PURE Bioscience (OTCMKTS:PURE) Releases Quarterly Earnings Results

PURE Bioscience (OTCMKTS:PURE) posted its earnings results on Monday. The company reported ($0.01) EPS for the quarter, Zacks reports.

PURE Bioscience Trading Up 25.1 %

Shares of PURE traded up $0.01 during mid-day trading on Monday, reaching $0.07. 1,477 shares of the stock traded hands, compared to its average volume of 58,446. The firm has a fifty day moving average price of $0.07 and a 200 day moving average price of $0.08. The company has a market cap of $7.70 million, a price-to-earnings ratio of -1.72 and a beta of 0.35. PURE Bioscience has a 1 year low of $0.05 and a 1 year high of $0.16.

PURE Bioscience Company Profile

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.